Rare disorder due to inadequate sharing of the placenta Advocacy Hub | UniteRare

At a Glance

Live from database

💊

3FDA treatments

Regulatory Watchboard

No FDA or trial events recorded yet for Rare disorder due to inadequate sharing of the placenta.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Rare disorder due to inadequate sharing of the placenta.
Check the disease page for updates →

Approved Treatments

3 FDA-approved

Sogroya

(somapacitan-beco)Orphan drugstandard

Novo Nordisk Pharmaceuticals

12.1 Mechanism of Action Somapacitan-beco binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transd...

FDA label ↗

Skytrofa

(lonapegsomatropin-tcgd)Orphan drugstandard

Ascendis Pharma Endocrinology Division A/S

Recombinant Human Growth Hormone [EPC]

12.1 Mechanism of Action SKYTROFA is a pegylated human growth hormone (somatropin) for once-weekly subcutaneous injection [see Clinical Pharmacology (...

FDA label ↗

Ngenla

(somatrogon-ghla)Orphan drugstandard

Pfizer Ireland Pharmaceuticals

12.1 Mechanism of Action Somatrogon-ghla binds to the GH receptor and initiates a signal transduction cascade culminating in changes in growth and met...

FDA label ↗

View full treatment details on disease page →